Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Fossils from China show complex life evolved millions of years earlier than once thought - 2This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
- 3Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- 4Kendall Jenner addresses long-standing rumor about her sexuality
- 5Strengthening through Wellness: Individual Preparation Achievement
- Artemis II astronauts make long-distance call to the space station as they head home from the moon
- Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- Carrefour becomes first European retailer to offer shopping on ChatGPT
- The most effective method to Explore Moral Situations in Brain research with Your Certification
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- How a Middle East War Becomes a Retail Price Hike
- The Tiny Channel Island With 65 Residents That Chefs And Foodies Go Out Of Their Way To Visit
- How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
